Darwin AG Launches Commercialization of Multi-Cancer Check — a Blood Test for Early Detection of 13 Types of Cancer

Munich, 18 March 2026 — 10:00 CET/CEST

Darwin AG (ISIN DE000A3C35W0) introduced its Multi-Cancer Check blood test for early cancer detection, developed with Wholomics GmbH and distributed through its 70% subsidiary NovoMedic GmbH. The test utilizes liquid biopsy technology and multi-omics analysis to simultaneously detect molecular signals from 13 cancer types, including colon, uterus, ovarian, lung, and bladder cancers.

Validation results from 862 samples (440 cancer cases) demonstrated 80.7% sensitivity with 99.1% specificity, achieving 82.5% sensitivity at stage I with only three false positives. The test examines over 150 metabolites and biomarkers using nuclear magnetic resonance, with an AI algorithm evaluating molecular signatures.

CEO Dr. Daniel Wallerstorfer stated: “Cancer survival rates depend largely on early detection” and emphasized the test’s combination of “high sensitivity in early stages and very high specificity.”

The global liquid biopsy market, valued at approximately USD 7 billion, is projected to reach over USD 22 billion by 2034, representing roughly 14% annual growth.

About Novogenia AG (formerly Darwin AG): The Novogenia Group, headquartered in Munich, operates in human genetics and personalized products based on genetic analysis. The company conducts genetic analyses for disease diagnosis, treatment, prevention, and produces customized nutritional supplements and cosmetics. Novogenia also invests in biotech, healthcare, and life sciences companies.

Contact:
Novogenia AG (Investor Relations)
Brienner Str. 7, 80333 Munich
Tel: +49 89 20 500 450
investor.relations@novogenia.com

Originally distributed via EQS News under the company's then-current name, Darwin AG. Source: eqs-news.com.